Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...
Although albuminuria and reduced glomerular filtration rate are believed to be markers of cardiovascular risk in individuals with type 2 diabetes, limited data on the association of these ...
Hosted on MSN1mon
Bayer aims to expand presence in India with new therapies and strategic collaborationsRecent product launches, including Kerendia (finerenone), Verquvo (vericiguat), and Nubeqa (darolutamide), reflect this strategy. Kerendia helps prevent or delay kidney failure in diabetic ...
(Circulation) In a prespecified analysis of the FINEARTS-HF trial, heart failure patients who received finerenone (Kerendia) had an initial decline in estimated glomerular filtration rate-- but it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback